Actinium Pharmaceuticals (ATNM) Receivables - Other (2011 - 2023)
Actinium Pharmaceuticals (ATNM) posted quarterly Receivables - Other of $307000.0 for Q2 2023, down 21.68% year-over-year from $392000.0 in Q2 2022, and up 0.99% quarter-over-quarter from $304000.0 in Q1 2023.
Actinium Pharmaceuticals (ATNM) Receivables - Other (2011 - 2023) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Receivables - Other for 8 consecutive years, with $307000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Receivables - Other fell 21.68% year-over-year to $307000.0; the TTM figure through Jun 2023 stood at $307000.0 (down 21.68% YoY), while the FY2022 annual figure was $302000.0, down 22.96% from the prior year.
- Receivables - Other advanced to $307000.0 in Q2 2023 per ATNM's latest filing, from $304000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $392000.0 in Q1 2021 and bottomed at $300000.0 in Q3 2022.
- Historically, Receivables - Other has averaged $371863.3 across 5 years, with a median of $391090.0 in 2019.
- Annual changes were most pronounced in 2021 — Receivables - Other advanced 0.26% — and 2022, when it decreased 23.47%.
- Actinium Pharmaceuticals' Receivables - Other stood at $391000.0 in 2019, then changed by 0.0% to $391000.0 in 2020, then rose by 0.26% to $392000.0 in 2021, then dropped by 22.96% to $302000.0 in 2022, then advanced by 1.66% to $307000.0 in 2023.
- Business Quant data shows ATNM's Receivables - Other at $307000.0 in Q2 2023, $304000.0 in Q1 2023, and $302000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 307,000.00 |
| Jun 30, 2023 | 307,000.00 |
| Mar 31, 2023 | 304,000.00 |
| Mar 31, 2023 | 304,000.00 |
| Dec 31, 2022 | 302,000.00 |
| Dec 31, 2022 | 302,000.00 |
| Sep 30, 2022 | 300,000.00 |
| Sep 30, 2022 | 300,000.00 |
| Jun 30, 2022 | 392,000.00 |
| Jun 30, 2022 | 392,000.00 |
| Mar 31, 2022 | 392,000.00 |
| Mar 31, 2022 | 392,000.00 |
| Dec 31, 2021 | 392,000.00 |
| Dec 31, 2021 | 392,000.00 |
| Sep 30, 2021 | 392,000.00 |
| Sep 30, 2021 | 392,000.00 |
| Jun 30, 2021 | 392,000.00 |
| Jun 30, 2021 | 392,000.00 |
| Mar 31, 2021 | 392,000.00 |
| Mar 31, 2021 | 392,000.00 |